Britain and Germany are pioneering comparative reviews of drugs' effectiveness and cost-benefit analyses aimed at reimbursing firms for new drugs based on how well they perform.
Whatever cost-benefit analyses are presented to them, the public, or at least that vocal section of it whose cries for law and order make penal reform electoral suicide, resent this expenditure.